Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study

Katie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

Blood (2024) 144 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2024-200997

Published: 2024

Journal Articles

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Ghaith Abu-Zeinah, Albert Qin, Harinder Gill, Norio Komatsu, John O. Mascarenhas, Weichung Joe Shih, Oleh Zagrijtschuk, Toshiaki Sato, Kazuya Shimoda, Richard T. Silver, Ruben A. Mesa

Blood (2024) 144 (Supplement 1): 3191.1.

https://doi.org/10.1182/blood-2024-200319

Published: 2024

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Journal Articles

DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha

Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Jr., Richard T. Silver, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 3190.

https://doi.org/10.1182/blood-2024-210703

Published: 2024

Journal Articles

Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Neville Lee, Jr., Katie Erdos, Aqib Abdul Rahman, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

Blood (2024) 144 (Supplement 1): 4568.

https://doi.org/10.1182/blood-2024-211143

Published: 2024

Journal Articles

Importance of Diagnosing Polycythemia Vera (PV) Patients (pts) Whose Hematocrit (HCT)/Hemoglobin (HGB) Are Less Than the Who 2022 Stipulated Criteria

Neville Lee, Jr., Katie Erdos, Joseph M. Scandura, Ghaith Abu-Zeinah, Richard T. Silver

Blood (2023) 142 (Supplement 1): 6434.

https://doi.org/10.1182/blood-2023-189643

Published: 2023

Journal Articles

Impact of Graft Source [Cord Blood Supported By CD34+ Selected Cells (Haplo-Cord) Vs. Matched Donor] on Transplant Outcomes in Myelofibrosis

Nima Ghalehsari, Zhengming Chen, Sebastian A. Mayer, Ghaith Abu-Zeinah, Tsiporah B. Shore, Ellen K. Ritchie, Richard T. Silver, Andrew I. Schafer, Joseph M. Scandura, Gail J. Roboz, Koen Van Besien, Alexandra Gomez-Arteaga

Blood (2023) 142 (Supplement 1): 6953.

https://doi.org/10.1182/blood-2023-185075

Published: 2023

Journal Articles

Marrow Hypercellularity Does Not Exclude the Diagnosis of Essential Thrombocythemia (ET)

Katie Erdos, Madhu M Ouseph, Julia Geyer, Neville Lee, Jr., Ghaith Abu-Zeinah, Joseph M. Scandura, Richard T. Silver

Blood (2023) 142 (Supplement 1): 3198.

https://doi.org/10.1182/blood-2023-187769

Published: 2023

Journal Articles

Low Thrombosis Risk CALR Mutations Confer Higher Risk of Essential Thrombocythemia Progression

Katie Erdos, Neville Lee, Jr., Ahamed Lebbe, Imane Bouhali, Mohammed Khalid, Ghaith Abu-Zeinah, Richard T. Silver, Joseph M. Scandura

Blood (2023) 142 (Supplement 1): 1819.

https://doi.org/10.1182/blood-2023-188952

Published: 2023

Journal Articles

Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2 V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Ghaith Abu-Zeinah, Franco Castillo Tokumori, Katie Erdos, Imane Bouhali, Daniel C Choi, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 6819–6820.

https://doi.org/10.1182/blood-2022-168283

Published: 2022

Journal Articles

Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis

Reem S. Chamseddine, Shehroz Rana, Mohammed Khalid, Nicole Kucine, Richard T. Silver, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2022) 140 (Supplement 1): 3999–4000.

https://doi.org/10.1182/blood-2022-168014

Published: 2022

Journal Articles

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

Ghaith Abu-Zeinah, Spencer Krichevsky, Katie Erdos, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 3961–3962.

https://doi.org/10.1182/blood-2022-170893

Published: 2022

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

Excess Mortality in Young Patients with Myeloproliferative Neoplasms

Khalid Abu-Zeinah, Khalil Saadeh, Richard T. Silver, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2021) 138 (Supplement 1): 235.

https://doi.org/10.1182/blood-2021-146029

Published: 2021

Journal Articles

Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival

Richard T. Silver, Elwood Taylor, III, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2021) 138 (Supplement 1): 2580.

https://doi.org/10.1182/blood-2021-149137

Published: 2021

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

Journal Articles

Normal Life Expectancy for Polycythemia Vera Patients Is Possible

Ghaith Abu-Zeinah, Richard T. Silver, Khalid Abu-Zeinah, Joseph Scandura

Blood (2021) 138 (Supplement 1): 2575.

https://doi.org/10.1182/blood-2021-147061

Published: 2021

Journal Articles

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients

Ghaith Abu-Zeinah, Spencer Krichevsky, Richard T. Silver, Elwood Taylor, III, Douglas Tremblay, Andrew Srisuwananukorn, John Mascarenhas, Joseph Scandura

Blood (2021) 138 (Supplement 1): 3619.

https://doi.org/10.1182/blood-2021-149098

Published: 2021

Journal Articles

Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs)

Ghaith Abu-Zeinah, Silvana Di Giandomenico, Tatiana Cruz, Daniel Choi, Elwood Taylor, III, Ellen Ritchie, Richard T. Silver, Joseph Scandura

Blood (2021) 138 (Supplement 1): 627.

https://doi.org/10.1182/blood-2021-153003

Published: 2021

Journal Articles

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ghaith Abu-Zeinah, MD, Spencer Krichevsky, BS, Tatiana Cruz, MD, Gabriela Hoberman, BA, Niamh Savage, BA, Ellen Ritchie, MD, Joseph Scandura, MDPhD, Richard T. Silver, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141796

Published: 2020

NARROW

Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study

HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha

Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Importance of Diagnosing Polycythemia Vera (PV) Patients (pts) Whose Hematocrit (HCT)/Hemoglobin (HGB) Are Less Than the Who 2022 Stipulated Criteria

Impact of Graft Source [Cord Blood Supported By CD34+ Selected Cells (Haplo-Cord) Vs. Matched Donor] on Transplant Outcomes in Myelofibrosis

Marrow Hypercellularity Does Not Exclude the Diagnosis of Essential Thrombocythemia (ET)

Low Thrombosis Risk CALR Mutations Confer Higher Risk of Essential Thrombocythemia Progression

Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2 V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Excess Mortality in Young Patients with Myeloproliferative Neoplasms

Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Normal Life Expectancy for Polycythemia Vera Patients Is Possible

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients

Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs)

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only